EdgarLookup

Unicycive Therapeutics, Inc. — All Filings

264 total filings on record

Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.

Overview All Filings Financials Insiders
All 10-K 10-Q 3 4 4/A 424B3 424B4 424B5 8-A12B 8-K 8-K/A ARS CERT CORRESP D DEF 14A DEFA14A DRS DRS/A DRSLTR EFFECT NT 10-Q POS AM PRE 14A S-1 S-1/A S-3 S-8 SC 13G SC 13G/A SCHEDULE 13G SCHEDULE 13G/A SEC STAFF LETTER UPLOAD
Form Description Accession Number Filed Period
SCHEDULE 13G/A 0001346824-26-000059 Feb 17, 2026
SCHEDULE 13G/A 0001104659-26-015349 Feb 13, 2026
SCHEDULE 13G/A 0001214659-26-001398 Feb 10, 2026
SCHEDULE 13G 0001104659-26-006264 Jan 23, 2026
SCHEDULE 13G/A 0001213900-25-111132 Nov 14, 2025
8-K CURRENT REPORT 0001213900-25-111045 Nov 14, 2025
424B5 PROSPECTUS SUPPLEMENT 0001213900-25-111042 Nov 14, 2025
SCHEDULE 13G/A 0001214659-25-016719 Nov 14, 2025
SCHEDULE 13G/A 0001104659-25-112646 Nov 14, 2025
SCHEDULE 13G/A 0001231919-25-000493 Nov 14, 2025
SCHEDULE 13G/A 0001814554-25-000178 Nov 14, 2025
8-K CURRENT REPORT 0001213900-25-108847 Nov 12, 2025
10-Q QUARTERLY REPORT 0001213900-25-108600 Nov 12, 2025 Sep 30, 2025
8-K CURRENT REPORT 0001213900-25-102790 Oct 28, 2025
4 0001213900-25-080808 Aug 26, 2025 Aug 25, 2025
8-K CURRENT REPORT 0001213900-25-077937 Aug 18, 2025 Aug 15, 2025
8-K CURRENT REPORT 0001213900-25-077497 Aug 15, 2025
SCHEDULE 13G/A 0001172661-25-003536 Aug 14, 2025
SCHEDULE 13G/A 0001104659-25-078704 Aug 14, 2025
SCHEDULE 13G/A 0000921895-25-002285 Aug 14, 2025
8-K CURRENT REPORT 0001213900-25-076066 Aug 14, 2025
10-Q QUARTERLY REPORT 0001213900-25-076007 Aug 14, 2025 Jun 30, 2025
SCHEDULE 13G/A 0001214659-25-011857 Aug 12, 2025
4 0001213900-25-069306 Jul 30, 2025 Jul 28, 2025
4 0001213900-25-069305 Jul 30, 2025 Jul 28, 2025
4 0001213900-25-069304 Jul 30, 2025 Jul 28, 2025
4 0001213900-25-069303 Jul 30, 2025 Jul 28, 2025
4 0001213900-25-069302 Jul 30, 2025 Jul 28, 2025
4 0001213900-25-069301 Jul 30, 2025 Jul 28, 2025
4 0001213900-25-069300 Jul 30, 2025 Jul 28, 2025
8-K CURRENT REPORT 0001213900-25-061936 Jul 8, 2025 Jul 7, 2025
8-K CURRENT REPORT 0001213900-25-059303 Jun 30, 2025
8-K CURRENT REPORT 0001213900-25-056188 Jun 20, 2025 Jun 17, 2025
424B5 PROSPECTUS SUPPLEMENT 0001213900-25-054305 Jun 13, 2025
8-K CURRENT REPORT 0001213900-25-052824 Jun 10, 2025
DEFA14A CURRENT REPORT 0001213900-25-052416 Jun 9, 2025
8-K CURRENT REPORT 0001213900-25-052413 Jun 9, 2025
DEFA14A DEFINITIVE ADDITIONAL MATERIALS 0001213900-25-046551 May 22, 2025
DEFA14A CURRENT REPORT 0001213900-25-046246 May 21, 2025
8-K CURRENT REPORT 0001213900-25-046244 May 21, 2025
SCHEDULE 13G/A 0001415889-25-013202 May 15, 2025
SCHEDULE 13G/A 0001104659-25-049529 May 15, 2025
SCHEDULE 13G/A 0001213900-25-043719 May 15, 2025
8-K CURRENT REPORT 0001213900-25-042967 May 14, 2025
10-Q QUARTERLY REPORT 0001213900-25-042943 May 14, 2025 Mar 31, 2025
DEFA14A DEFINITIVE ADDITIONAL MATERIALS 0001213900-25-040661 May 7, 2025
ARS ARS 0001213900-25-037622 Apr 30, 2025 Dec 31, 2024
DEF 14A DEFINITIVE PROXY STATEMENT 0001213900-25-037613 Apr 30, 2025 Jun 9, 2025
PRE 14A PRELIMINARY PROXY STATEMENT 0001213900-25-033307 Apr 18, 2025
8-K/A AMENDMENT NO. 1 TO FORM 8-K 0001213900-25-031593 Apr 14, 2025 Mar 13, 2024